% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

  • galaberge galaberge Mar 18, 2013 9:45 PM Flag

    QIDP is coming from "Legislative Notice: S. 3187 – The Food and Drug Administration Safety and Innovation Act"

    Section 801

    This section offers incentives to develop new qualified infectious disease products (QIDPs). This section provides an additional five year market exclusivity period – in addition to other exclusivity periods for which the product might qualify. It also clearly defines QIDPs as antibacterial or antifungal drugs intended to treat serious or life-threatening infections.

    Section 802

    This section makes QIDPs eligible for priority review.

    Section 803

    This section makes QIDPs eligible for fast track review.

    Sentiment: Strong Buy